Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 64479

Title: Molecular regulation mechanism of ferroptosis and its role in gastrointestinal oncology: Progress and updates

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03478911
Position: Editorial Board
Academic degree: PhD
Professional title: Chief Technician, Executive Vice President, Research Assistant Professor
Reviewer's Country/Territory: South Korea
Author's Country/Territory: China

Manuscript submission date: 2021-04-20
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-04-20 08:33
Reviewer performed review: 2021-04-27 05:29
Review time: 6 Days and 20 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this review, the authors summarized recent research progress on the mechanism of ferroptosis and its role in gastrointestinal tumors. Ferroptosis is characterized by iron accumulation, excessive ROS production, and overwhelming lipid peroxidation, and is well known for a specific mechanism of sorafenib, but it is a mechanism that has recently attracted attention in the area of gastrointestinal disease, especially cancer. The topic is very appropriate, but there are some issues to raise. 1. The main content was not focused on gastrointestinal cancer. In the "Introduction" section, it is necessary to supplement the non-clinical and clinical background why ferroptosis is attention in gastrointestinal cancer in detail. 2. Most of the content that follows the Introduction section is the general theory of Ferroptosis. Therefore, an association with gastrointestinal cancer must be included in each paragraph. 3. The full contents must be filled out from the table indicated by the author. The origin and mode of action of each inducer and inhibitor, as well as many applications including gastrointestinal cancer, must be described. Please refer to the section “FERROPTOSIS INDUCERS AND INHIBITORS”. 4. It is recommended to separate the CRC from the gastric cancer section. Please refer to the section “Ferroptosis and other GI tumors”. 5. The clinical cases that utilize the mechanism of ferroptosis must be summarized separately (eg Sorafenib, Cisplatin). Please cite the following reference: Yanwei Su, et. Al., Volume 483, 28 July 2020, Pages 127-136, Cancer Letters.